New strategies for human papillomavirus-based cervical screening

Women's Health

Volumn 9, Issue 5, 2013, Pages 443-452

  Lorincz, Attila ^a   Castanon, Alejandra ^a   Wey Lim, Anita Wey ^a   Sasieni, Peter ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

cancer prevention; human papillomavirus testing; screening for cervical cancer; triage of hrHPV positive women; vaginal self sampling

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; KI 67 ANTIGEN; VIRUS DNA;

CANCER GRADING; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; COLPOSCOPY; COMPARATIVE STUDY; COST CONTROL; DNA DETERMINATION; DNA METHYLATION; FEMALE; GENOTYPE; GYNECOLOGICAL AND OBSTETRIC SAMPLING DEVICE; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOCYTOCHEMISTRY; LOWEST INCOME GROUP; NONHUMAN; PAPILLOMAVIRUS INFECTION; PATIENT IDENTIFICATION; PATIENT PARTICIPATION; PELVIC EXAMINATION; REVIEW; SAMPLING; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VAGINAL SELF COLLECTION; VIRUS EXAMINATION; VISUAL INSPECTION AFTER APPLICATION OF ACETIC ACID; WART VIRUS;

CERVICAL INTRAEPITHELIAL NEOPLASIA; CYTOLOGICAL TECHNIQUES; DNA METHYLATION; DNA, VIRAL; FEMALE; GENES, P16; GENOTYPE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TIME FACTORS; VAGINAL SMEARS; WOMEN'S HEALTH;

EID: 84883606866     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.13.48     Document Type: Review

References (83)

1. McCredie MR, Sharples KJ, Paul C et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: A retrospective cohort study. Lancet Oncol. 9(5), 425-434 (2008).
2. Sasieni P, Castanon A, Parkin DM. How many cervical cancers are prevented by treatment of screen-detected disease in young women? Int. J. Cancer 124(2), 461-464 (2009).
3. Soutter WP, Sasieni P, Panoskaltsis T. Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia. Int. J. Cancer 118(8), 2048-2055 (2006).
4. Evans HS, Newnham A, Hodgson SV, Moller H. Second primary cancers after cervical intraepithelial neoplasia III and invasive cervical cancer in southeast England. Gynecol. Oncol. 90(1), 131-136 (2003). (Pubitemid 37338087)
5. Karnon J, Peters J, Platt J, Chilcott J, McGoogan E, Brewer N. Liquid-based cytology in cervical screening: An updated rapid and systematic review and economic analysis. Health Technol. Assess. 8(20), iii, 1-78 (2004).
6. Walboomers JM, Jacobs MV, Manos MM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189(1), 12-19 (1999). (Pubitemid 29406813)
7. Moscicki AB, Shiboski S, Broering J et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J. Pediatr. 132(2), 277-284 (1998). (Pubitemid 28125180)
8. Szarewski A, Mesher D, Cadman L et al. A comparison of seven tests for high grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study. J. Clin. Microbiol. 50(6), 1867-1873 (2012).
9. Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: A subanalysis of the ATHENA study. Lancet Oncol. 12(9), 880-890 (2011).
10. Cuzick J, Arbyn M, Sankaranarayanan R et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 26(Suppl. 10), K29-K41 (2008).
11. Cuzick J, Clavel C, Petry KU et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int. J. Cancer 119(5), 1095-1101 (2006). (Pubitemid 44116919)
12. Leinonen M, Nieminen P, Kotaniemi-Talonen L et al. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J. Natl Cancer Inst. 101(23), 1612-1623 (2009).
13. Snijders PJ, Verhoef VM, Arbyn M et al. High-risk HPV testing on self-sampled versus clinician-collected specimens: A review on the clinical accuracy and impact on population attendance in cervical cancer screening. Int. J. Cancer 132(10), 2223-2236 (2013).
14. Dillner J, Rebolj M, Birembaut P et al. Long-term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 337, a1754 (2008).
15. Mesher D, Szarewski A, Cadman L et al. Long-term follow-up of cervical disease in women screened by cytology and HPV testing: results from the HART study. Br. J. Cancer 102(9), 1405-1410 (2010).
16. Sherman ME, Lorincz AT, Scott DR et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: A 10 year cohort analysis. J. Natl Cancer Inst. 95(1), 46-52 (2003). (Pubitemid 36124295)
17. Kjaer S, Hogdall E, Frederiksen K et al. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res. 66(21), 10630-10636 (2006). (Pubitemid 44799787)
18. Katki HA, Kinney WK, Fetterman B et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: A population-based study in routine clinical practice. Lancet Oncol. 12(7), 663-672 (2011).
19. Kitchener HC, Almonte M, Thomson C et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): A randomised controlled trial. Lancet Oncol. 10(7), 672-682 (2009).
20. Naucler P, Ryd W, Tornberg S et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N. Engl. J. Med. 357(16), 1589-1597 (2007). (Pubitemid 47598401)
21. Rijkaart DC, Berkhof J, Rozendaal L et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 13(1), 78-88 (2012).
22. Ronco G, Giorgi-Rossi P, Carozzi F et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: A randomised controlled trial. Lancet Oncol. 11(3), 249-257 (2010).
23. Almonte M, Ferreccio C, Winkler JL et al. Cervical screening by visual inspection, HPV testing, liquid-based and conventional cytology in Amazonian Peru. Int. J. Cancer 121(4), 796-802 (2007). (Pubitemid 47106209)
24. Sankaranarayanan R, Nene BM, Shastri SS et al. HPV screening for cervical cancer in rural India. N. Engl. J. Med. 360(14), 1385-1394 (2009).
25. Naucler P, Ryd W, Tornberg S et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J. Natl Cancer Inst. 101(2), 88-99 (2009).
26. Saslow D, Solomon D, Lawson HW; ACS-ASCCP-ASCP Cervical Cancer Guideline Committee et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J. Clin. 62(3), 147-172 (2012).
27. Sasieni P, Cuzick J. Could HPV testing become the sole primary cervical screening test? J. Med. Screen. 9(2), 49-51 (2002). (Pubitemid 34816250)
28. Rijkaart DC, Berkhof J, van Kemenade FJ et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int. J. Cancer 130(3), 602-610 (2012).
29. Schiffman M, Herrero R, Desalle R et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 337(1), 76-84 (2005). (Pubitemid 40725441)
30. Kjaer SK, Frederiksen K, Munk C, Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J. Natl Cancer Inst. 102(19), 1478-1488 (2010).
31. de Sanjose S, Quint WG, Alemany L et al. Human papillomavirus genotype attribution in invasive cervical cancer: A retrospective cross-sectional worldwide study. Lancet Oncol. 11(11), 1048-1056 (2010).
32. Bosch FX, Manos MM, Munoz N et al. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J. Natl Cancer Inst. 87(11), 796-802 (1995).
33. Khan MJ, Castle PE, Lorincz AT et al. The elevated 10 year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl Cancer Inst. 97(14), 1072-1079 (2005). (Pubitemid 41417924)
34. Negri G, Bellisano G, Zannoni GF et al. p16 ink4a and HPV L1 immunohistochemistry is helpful for estimating the behavior of low-grade dysplastic lesions of the cervix uteri. Am. J. Surg. Pathol. 32(11), 1715-1720 (2008).
35. Ozaki S, Zen Y, Inoue M. Biomarker expression in cervical intraepithelial neoplasia: potential progression predictive factors for low-grade lesions. Hum. Pathol. 42(7), 1007-1012 (2011).
36. Wang JL, Zheng BY, Li XD, Angstrom T, Lindstrom MS, Wallin KL. Predictive significance of the alterations of p16INK4A, p14ARF, p53, and proliferating cell nuclear antigen expression in the progression of cervical cancer. Clin. Cancer Res. 10(7), 2407-2414 (2004). (Pubitemid 38445700)
37. Denton KJ, Bergeron C, Klement P, Trunk MJ, Keller T, Ridder R. The sensitivity and specificity of p16(INK4a) cytology vs HPV testing for detecting high-grade cervical disease in the triage of ASC-US and LSIL Pap cytology results. Am. J. Clin. Pathol. 134(1), 12-21 (2010).
38. Carozzi F, Confortini M, Dalla Palma P et al. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: A nested substudy of the NTCC randomised controlled trial. Lancet Oncol. 9(10), 937-945 (2008).
39. Bergeron C, Ordi J, Schmidt D, Trunk MJ, Keller T, Ridder R. Conjunctive p16INK4a testing significantly increases accuracy in diagnosing high-grade cervical intraepithelial neoplasia. Am. J. Clin. Pathol. 133(3), 395-406 (2010).
40. Petry KU, Schmidt D, Scherbring S et al. Triaging pap cytology negative, HPV-positive cervical cancer screening results with p16/Ki-67 dual-stained cytology. Gynecol. Oncol. 121(3), 505-509 (2011).
41. Schmidt D, Bergeron C, Denton KJ, Ridder R; European CINtec Cytology Study Group. p16/Ki-67 dual-stain cytology in the triage of ASCUS and LSIL papanicolaou cytology: results from the European equivocal or mildly abnormal Papanicolaou cytology study. Cancer Cytopathol. 119(3), 158-166 (2011).
42. Tsoumpou I, Arbyn M, Kyrgiou M et al. p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: A systematic review and meta-analysis. Cancer Treat. Rev. 35(3), 210-220 (2009).
43. Carozzi F, Gillio-Tos A, Confortini M et al. Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: A prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncol. 14(2), 168-176 (2013).
44. Lorincz AT. The promise and the problems of epigenetics biomarkers in cancer. Expert Opin. Med. Diagn. 5(5), 375-379 (2011).
45. Wentzensen N, Sherman ME, Schiffman M, Wang SS. Utility of methylation markers in cervical cancer early detection: Appraisal of the state-of-the-science. Gynecol. Oncol. 112(2), 293-299 (2009).
46. Hesselink AT, Heideman DA, Steenbergen RD et al. Combined promoter methylation analysis of CADM1 and MAL: An objective triage tool for high-risk human papillomavirus DNA-positive women. Clin. Cancer Res. 17(8), 2459-2465 (2011).
47. Kalantari M, Calleja-Macias IE, Tewari D et al. Conserved methylation patterns of human papillomavirus type 16 DNA in asymptomatic infection and cervical neoplasia. J. Virol. 78(23), 12762-12772 (2004). (Pubitemid 39507784)
48. Brandsma JL, Sun Y, Lizardi PM et al. Distinct human papillomavirus type 16 methylomes in cervical cells at different stages of premalignancy. Virology 389(1-2), 100-107 (2009).
49. Mirabello L, Sun C, Ghosh A et al. Methylation of human papillomavirus type 16 genome and risk of cervical precancer in a Costa Rican population. J. Natl Cancer Inst. 104(7), 556-565 (2012).
50. Lorincz AT, Brentnall AR, Vasiljevic N et al. HPV16 L1 and L2 DNA methylation predicts high-grade cervical intraepithelial neoplasia in women with mildly abnormal cervical cytology. Int. J. Cancer, 133(3), 637-644 (2013).
51. Sasieni PD, Cuzick J, Lynch-Farmery E. Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The National Co-ordinating Network for Cervical Screening Working Group. Br. J. Cancer 73(8), 1001-1005 (1996). (Pubitemid 26116757)
52. Szarewski A, Cadman L, Ashdown-Barr L, Waller J. Exploring the acceptability of two self-sampling devices for human papillomavirus testing in the cervical screening context: A qualitative study of Muslim women in London. J. Med. Screen. 16(4), 193-198 (2009).
53. Igidbashian S, Boveri S, Spolti N, Radice D, Sandri MT, Sideri M. Self-collected human papillomavirus testing acceptability: comparison of two self-sampling modalities. J. Womens Health (Larchmt) 20(3), 397-402 (2011).
54. Waller J, McCaffery K, Forrest S et al. Acceptability of unsupervised HPV self-sampling using written instructions. J. Med. Screen. 13(4), 208-213 (2006). (Pubitemid 46057729)
55. Gravitt PE, Belinson JL, Salmeron J, Shah KV. Looking ahead: A case for human papillomavirus testing of self-sampled vaginal specimens as a cervical cancer screening strategy. Int. J. Cancer 129(3), 517-527 (2011).
56. Dzuba IG, Diaz EY, Allen B et al. The acceptability of self-collected samples for HPV testing vs. The pap test as alternatives in cervical cancer screening. J. Womens Health Gend. Based Med. 11(3), 265-275 (2002).
57. Barata PC, Mai V, Howlett R, Gagliardi AR, Stewart DE. Discussions about self-obtained samples for HPV testing as an alternative for cervical cancer prevention. J. Psychosom. Obstet. Gynaecol. 29(4), 251-257 (2008).
58. Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ et al. Primary screening for high risk HPV by home obtained cervicovaginal lavage is an alternative screening tool for unscreened women. J. Clin. Pathol. 55(6), 435-439 (2002). (Pubitemid 34620780)
59. Anhang R, Nelson JA, Telerant R, Chiasson MA, Wright TC Jr. Acceptability of self-collection of specimens for HPV DNA testing in an urban population. J. Womens Health (Larchmt) 14(8), 721-728 (2005). (Pubitemid 41645634)
60. Berner A, Hassel SB, Tebeu PM et al. Human papillomavirus self-sampling in Cameroon: women's uncertainties over the reliability of the method are barriers to acceptance. J. Low. Genit. Tract Dis. 17(3), 235-241 (2013).
61. Mitchell S, Ogilvie G, Steinberg M, Sekikubo M, Biryabarema C, Money D. Assessing women's willingness to collect their own cervical samples for HPV testing as part of the ASPIRE cervical cancer screening project in Uganda. Int. J. Gynaecol. Obstet. 114(2), 111-115 (2011).
62. Forrest S, McCaffery K, Waller J et al. Attitudes to self-sampling for HPV among Indian, Pakistani, African-Caribbean and white British women in Manchester, UK. J. Med. Screen. 11(2), 85-88 (2004). (Pubitemid 38829885)
63. Howard M, Lytwyn A, Lohfeld L, Redwood-Campbell L, Fowler N, Karwalajtys T. Barriers to acceptance of self-sampling for human papillomavirus across ethnolinguistic groups of women. Can. J. Public Health 100(5), 365-369 (2009).
64. Waller J, Bartoszek M, Marlow L, Wardle J. Barriers to cervical cancer screening attendance in England: A population-based survey. J. Med. Screen. 16(4), 199-204 (2009).
65. Petignat P, Faltin DL, Bruchim I, Tramer MR, Franco EL, Coutlee F. Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis. Gynecol. Oncol. 105(2), 530-535 (2007). (Pubitemid 46590347)
66. Ogilvie GS, Patrick DM, Schulzer M et al. Diagnostic accuracy of self collected vaginal specimens for human papillomavirus compared with clinician collected human papillomavirus specimens: A meta-analysis. Sex. Transm. Infect. 81(3), 207-212 (2005). (Pubitemid 40835044)
67. Stewart DE, Gagliardi A, Johnston M et al. Self-collected samples for testing of oncogenic human papillomavirus: A systematic review. J. Obstet. Gynaecol. Can. 29(10), 817-828 (2007).
68. Castle PE, Rodriguez AC, Porras C et al. A comparison of cervical and vaginal human papillomavirus. Sex. Transm. Dis. 34(11), 849-855 (2007). (Pubitemid 350301046)
69. Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A et al. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): A community-based randomised controlled trial. Lancet 378(9806), 1868-1873 (2011).
70. Zhao FH, Lewkowitz AK, Chen F et al. Pooled analysis of a self-sampling HPV DNA test as a cervical cancer primary screening method. J. Natl Cancer Inst. 104(3), 178-188 (2012).
71. Holanda F Jr, Castelo A, Veras TM, de Almeida FM, Lins MZ, Dores GB. Primary screening for cervical cancer through self sampling. Int. J. Gynaecol. Obstet. 95(2), 179-184 (2006). (Pubitemid 44635514)
72. Qiao YL, Sellors JW, Eder PS et al. A new HPV-DNA test for cervical-cancer screening in developing regions: A cross-sectional study of clinical accuracy in rural China. Lancet Oncol. 9(10), 929-936 (2008).
73. Giorgi Rossi P, Marsili LM, Camilloni L et al. The effect of self-sampled HPV testing on participation to cervical cancer screening in Italy: A randomised controlled trial (ISRCTN96071600). Br. J. Cancer 104(2), 248-254 (2011).
74. Szarewski A, Cadman L, Mesher D et al. HPV self-sampling as an alternative strategy in non-attenders for cervical screening - a randomised controlled trial. Br. J. Cancer 104(6), 915-920 (2011).
75. Bais AG, van Kemenade FJ, Berkhof J et al. Human papillomavirus testing on self-sampled cervicovaginal brushes: An effective alternative to protect nonresponders in cervical screening programs. Int. J. Cancer 120(7), 1505-1510 (2007). (Pubitemid 46355385)
76. Sanner K, Wikstrom I, Strand A, Lindell M, Wilander E. Self-sampling of the vaginal fluid at home combined with high-risk HPV testing. Br. J. Cancer 101(5), 871-874 (2009).
77. Gok M, Heideman DA, van Kemenade FJ et al. HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ 340, c1040 (2010).
78. Gok M, Heideman DA, van Kemenade FJ et al. Offering self-sampling for human papillomavirus testing to non-attendees of the cervical screening programme: characteristics of the responders. Eur. J. Cancer 48(12), 1799-1808 (2012).
79. Virtanen A, Anttila A, Luostarinen T, Nieminen P. Self-sampling versus reminder letter: effects on cervical cancer screening attendance and coverage in Finland. Int. J. Cancer 128(11), 2681-2687 (2011).
80. Wikstrom I, Lindell M, Sanner K, Wilander E. Self-sampling and HPV testing or ordinary Pap-smear in women not regularly attending screening: A randomised study. Br. J. Cancer 105(3), 337-339 (2011).
81. Virtanen A, Nieminen P, Luostarinen T, Anttila A. Self-sample HPV tests as an intervention for nonattendees of cervical cancer screening in Finland: A randomized trial. Cancer Epidemiol. Biomarkers Prev. 20(9), 1960-1969 (2011).
82. de Kok IM, Van Rosmalen J, Dillner J et al. Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model. BMJ 344, e670 (2012).
83. Ferlay JSH, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 (2010). http://globocan.iarc.fr